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Objective: The aim of this study was to analyze the prevalence of HPV and EBV in oral and oropharyngeal squamous
cell carcinoma in south-eastern Poland. The correlation between viral infection, OSCC, alcohol use, tobacco smoking,
demographic data (gender, age, place of residence), anatomic location, pre-treatment staging, evidence of metastases
to lymph nodes, and grading was also investigated.
Methods: The examination samples were collected from paraffin tissue blocks, from 154 patients. Viral DNA was
amplified by the nested-PCR method.
Results: HPV DNA was detected in 29.2 % of the tested samples (in 27.4 % of oropharyngeal and in 30.4 % of oral
cavity). The HPV type 16 was detected in 15.6 % of all samples, and in 53.3 % of HPV-positive group. In HPV-positive
samples from oropharyngeal HPV 16 constitute 76.5 %, and in HPV-positive samples from oral cavity HPV 16 constitute
39.3 %. Mixed infection (more than one type of HPV) was observed in 23.5 and 60.7 %, respectively, and in 46.7 % of all
HPV-positive samples, and in 12.3 % of the whole study group. EBV DNA was detected in 27.3 % of the cases and
HPV-EBV co-infection in 7.8 % of samples.
Conclusions: In major patients from Southeastern region of Poland with oropharyngeal cancer HPV type 16 was
detected but in oral cavity cancer other mixed infections were observed (i.e. 51, 52, 59, 66, 68, 71, 74). HPV 16 was
detected more often among patients younger than 50 years of age, whereas the mixed HPV in the group aged
50–59. The pathogenesis of oral squamous cell carcinoma may be connected with EBV infection. Future studies on the
mechanisms of HPV/EBV co-infection and/or superinfection and their role in oral squamous cell carcinoma are
necessary.
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Co-infectionIntroduction
Oral squamous cell carcinoma (OSCC) is a serious public
health problem in many parts of the world and in Poland
too. In Poland oral and oropharyngeal cancer constitutes
3.8 % cancers among men and 1.3 % cancers among
women [1]. Oral and oropharyngeal squamous cell carcin-
oma (OSCC) in tumor histology accounts for more than
90 % of the cases [2]. The etiology of OSCC is considered
to be multifactorial and the factors influencing it include* Correspondence: m.polz@umlub.pl
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etic alterations. The main predisposing factors are tobacco
and alcohol abuse [3]. An important role in the etiology of
many of them is played by the oncogenic viruses [2]. The
cancerogenecity of HPV in humans was conducted by the
International Agency for Research on Cancer (IARC) in
2007 and 2012 [4, 5].
The first original observation that implicated HPV as a
risk factor in the development of oral cancer was pre-
sented by Syrjänen et al. in 1983 [6]. Since then, several
studies have focused on HPV detection in oral cancer [7].
A more recent study by Syrjänen and Syrjänen showed a
strong association between the presence of HPV DNA,article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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showed that HPV significantly increases the risk for OSCC,
as compared with controls. HPV positive oropharyngeal
cancer varied according to the geographical region, i.e. in
North America – 56 %, in Japan 52 %, in Australia 45 %, in
Northern and West Europe 38 % [9].
Epstein-Barr virus, which is also known as human her-
pesvirus 4 (HHV-4) and which belongs to the Herpesvir-
idae family, has a double-stranded DNA genome [10].
EBV is an enveloped virus with icosahedral capsids sym-
metry and the genome takes on a linear form in mature
virions and a circular episomal form during the period
of latency in the infected cells. This is one of the most
common viruses in humans [11]. EBV was the first hu-
man virus to which the oncogenic potential was attrib-
uted, and it is classified as group 1 carcinogen by the
World Health Organization’s International Agency for
Research on Cancer [12]. EBV is correlated with
nasopharyngeal and gastric carcinoma, squamous cell
carcinoma, Hodgkin’s lymphoma, and Burkitt’s lymph-
oma [10, 13–15]. Current investigations suggest that
EBV is correlated with many diseases localized in the oral
cavity such as gingivitis, periodontitis, pulpitis, periapical
inflammations and periodontal abscesses [14, 16]. A lot of
studies indicate co-infection with HPV and EBV viruses in
oral squamous cell carcinoma [17, 18].
The aim of this study was to analyze the prevalence of
HPV and EBV and their co-infection in oral and oropha-
ryngeal squamous cell carcinoma in south-eastern Poland.
Material and methods
Sample collection
Tissue samples were obtained from 154 patients with
primary oral and oropharyngeal SCC treated in the
Chair and Department of Otolaryngology and Laryngo-
logical Oncology of the Medical University of Lublin.
Samples were collected in 2006–2009. The group con-
sisted of 131 males and 23 females, aged between 40
and 87 (average 56.8 years). In the examination group
there were 92 patients with oral, and 62 with oropha-
ryngeal SCC. It was a retrospective investigation and
the examined materials were obtained from formalin-
fixed, paraffin-embedded tissues. The samples were col-
lected during surgery, but TNM was calculated during
primary diagnosis (T-tumor, N-nodus, M-metastasis).
One hundred percent of the patients were classified as
N0, M0. The patients were treated surgically with or
without postoperative radiotherapy, depending on the
clinical stage of the disease. The patients did not re-
ceive radiotherapy or chemotherapy before. TNM clas-
sification was done according to the criteria of the
Union Against Cancer (UICC) [19]. Histological grad-
ing was performed according to the World Health
Organization criteria, which divide tumors into threetypes: well differentiated (G1), moderately differentiated
(G2), and poorly differentiated (G3) [20].
This research was approved by the Ethics Committee
and it was is in accordance with the GCP regulations
(no. KE-0254/181/2012).
DNA extraction from paraffin sections
We used 5 × 10-μm sections of formalin-fixed, paraffin-
embedded tissues from OSCC samples. DNA was ex-
tracted using a protocol as described in the DNeasy Tissue
Kit Handbook (Qiagen GmBH, Hilden, Germany, cat. No
69506). Purified DNA was quantified by spectrophotom-
etry (Epoch Microplate Spectrophotometr, BioTek Instru-
ments Inc., Vinooski, Vermont USA).
EBV DNA detection
The nested PCR was carried out for detection of EBV
DNA. The product size was 54 bp. The primer sequences
are:
Outer
5′ – GTC ATC TAC GGG GAC ACG GA – 3′
5′ – AAG AAG AGA TAT GTG GGG GT – 3′
Inner
5′ – ACC CGG AGC CTG TTT GTG GC– 3′
5′ – GGA GAA GGT CTT CTC GGC CTC – 3′
All PCR reactions were carried out in the final volume
of 25 μl using Taq PCR Core Kit (Qiagen, Hilden,
Germany). Concentrations of PCR reaction components
were prepared as follows: 2 mM MgCl2, 0.2 mM dNTPs,
0.2 μM of each forward and reverse primers and 0.5 U of
Taq DNA polymerase. During each run the samples were
tested together with one negative and one positive control.
The negative control consisted of nuclease-free water,
positive - EBV-positive cell line, Namalwa, ATCC-CRL-
1432. The reaction mixture containing 5 μl of extracted
DNA was amplified under the following conditions: 94 °C
for 3 min of initial denaturation, then 35 cycles of 94 °C
for 30 s, 55 °C for 40 s, 72 °C for 1 min with the final ex-
tension at 72 °C for 5 min. The second round amplifica-
tion was performed with 1 μl of the outer product in the
same conditions. The final PCR products were analysed
on 3 % agarose gel.
HPV DNA detection; HPV detection and genotyping
was performed using the INNO-LiPA HPV Genotyping
Extraassay (Innogenetics N. V, Gent, Belgium; no cat.
81063) according to the manufacturer’s protocol. The kit
is based on the amplification of a 65 bp fragment from the
L1 region of the HPV genome. PCR products are subse-
quently typed with the reverse hybridization assay. The
assay covers all currently known high-risk HPV geno-
types and probable high-risk HPV genotypes (16, 18, 26,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as
well as a number of low-risk HPV genotypes (6, 11, 40, 43,
44, 54, 70) and some additional types (69, 71, 74).
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Statistical analysis was performed to investigate the rela-
tionship between EBV and HPV presence and clinical
and demographical characteristics of patients were de-
termined by means of Pearson’s chi-square test and with
Fisher’s exact test for small groups. Statistical signifi-
cance was defined as p < 0.05.Results
Males (85.1 %) with, smoking (85.0 %) and alcohol abuse
(64.3 %) problems prevailed in the studied group. The
majority of the tumors in the examination group were
classified as G2 (81.8 %). T4 (58.4 %) and N2 (50.0 %)
traits occurred in the majority of patients. No cases of
metastasis were observed (M0 100 %). Characteristics of
the study group are shown in Table 1. In the Fig. 1 the
prevalence of HPV, EBV and HPV/EBV co-infection
were presented.Table 1 Epidemiological and clinical characteristics of patients
Oropharynx
N = 62 %
Sex female 6 9.7
male 56 90.3
Age 40–49 12 19.3
50–59 46 74.2
70 + 4 6.5
Place of residence urban 37 59.7
rural 25 40.3
Smoking yes 52 83.9
no 3 4.8
No answer 7 11.3
Alkohol abuse yes 42 67,7
No 7 11.3
No answer 13 21.0
Histology stage G 1 2 3.2
2 50 80.6
3 10 16.2








M stage 0 62 100.0
1 0 0Of all 154 samples, 29.2 % (45/154) were HPV positive,
27.4 % (17/62) in oropharyngeal and 30.4 % (28/92) in oral
cavity cancer. HPV type 16 was detected in 20.9 % (13/62)
of oropharyngeal and in 12 % (11/92) of oral cancer. The
HPV type 16 was detected in 53.3 % of HPV-positive
group; in oropharyngeal more often (76.5 %) than in sam-
ples from the oral cavity (39.3 %). This difference is statis-
tically significant (p < 0.01). Other mixed infections (more
than one type of HPV i.e. 51, 52, 59, 66, 68, 71, 74) were
detected in 23.5 and 60.7 % of the cases, respectively, and
in 46.7 % of all HPV-positive samples.
Of all investigated samples, 27.3 % were positive for
EBV, in oropharyngeal 29.1 % and in oral cavity 26.1 %.
Co-infection HPV/ EBV was detected in 7.8 % (12/154), in
oropharyngeal 9.7 % (6/62) and in the oral cavity
6.5 % (6/92). EBV and HPV 16 co-infection was detected
in 6 cases i.e. 50.0 % of co-infected samples. There are no
correlation between HPV or EBV infection and age and
tobacco smoking (Table 2). Table 3 shows the prevalenceOral cavity Total
N = 92 % N = 154 %
17 18.5 23 14.9
75 81.5 131 85.1
23 25.0 35 22.8
60 65.2 106 68.8
9 9.8 13 8.4
55 59.8 92 59.7
37 40.2 62 40.3
79 85.9 131 85.1
5 5.4 8 5.2
8 8.7 15 9.7
57 62.0 99 64.3
6 6.5 13 8.4
29 31.5 42 27.3
12 13.0 14 9.1
76 82.6 126 81.8
4 4.4 14 9.1
0 0 0 0
31 33.7 33 21.4
19 20.7 31 20.2
42 45.6 90 58.4
19 20.6 30 19.5
18 19.6 32 20.8
42 45.7 77 50.0
13 14.1 15 9.7
92 100.0 154 100.0







HPV16 HPVmix EBV HPV+EBV
Chart Title
Oropharynx oral cavity
Fig. 1 Prevalence of HPV, EBV and HPV/EBV coinfection in oropharyngeal and oral cavity cancer (%)
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TN classification. Among HPV-positive patients G1 was
diagnosed more often (15.6 %) than among HPV-negative
ones (6.4 %), and G3 more often in HPV-negative. There
is a statistically significant (p < 0.05).Discussion
The prevalence of HPV in squamous cell carcinoma of the
oral and oropharynx is diverse and ranges from 8 to 74 %
[21–24]. This is the first original observation about fre-
quency of HPV and EBV in oral and oropharyngeal cancer
among Polish patients. In our study HPV DNA was de-
tected in 29.2 % of the tested samples (27.4 % - orophar-
ynx; 30.4 % - oral cavity) and is lower than in Northern
and Western Europe. Poland is located in East Europe, so
prevalence of HPV be able to different than in otherTable 2 HPV 16, HPV other and EBV by age and smoking
Age HPV 16 HPV mix EBV
N = 24 N = 21 N = 42
40–49 8 (22.9 %) 6 (17.1 %) 5 (14.3 %)
N = 35
50–59 13 (12.3 %) 15 (14.2 %) 33 (31.4 %)
N = 106
70+ 3 (23.1 %) 0 4 (30.8 %)
N = 13
p >0.05 >0.05 >0.05
Smoking 20 (83.3 %) 15 (71.4 %) 32 (76.2 %)
Yes
N = 131
No 4 (16.7 %) 6 (28.6 %) 10 (23.8 %)
N = 23
p >0.05 >0.05 >0.05European countries. HPV infection is a sexually transmit-
ted infection, so sexual behaviors can play a role.
Studies by Robinson et al. [25] did not reveal any asso-
ciation between the histological grade and HPV status in
these tumours. Instead, Zhao et al [26] by multivariate
analysis have found a correlation between HPV infection
and poor histological grade (OR = 104.0, 95 % CI: 11.2–
962.1). His study provides evidence that the presence of
HPV predicted a better survival.
In the present study a significant relationship was found
between the status of HPV and the poor histopathological
grades (chi square, p < 0.05; Table 3). In most studies no
association was found between HPV presence and TNM
clinical stage [26]. Our results are similar.
Confirmation or exclusion of HPV DNA in OSCC influ-
ences prognosis and therapy choices. Some researchers
state that OSCC patients who are HPV-positive have a
more favorable treatment prognosis [20–22], higher sur-
vival rates and a lower risk of the disease recurrence in
comparison to the HPV-negative patients [27]. Addition-
ally, such patients do not require radio or chemotherapy
afterwards [28], and according Khode [29] HPV-positive
tumors are more sensitive to chemotherapy.
Although squamous cell carcinoma has been commonly
believed to affect people above fifty, the newest data indi-
cate that the age of people afflicted with this disease is
constantly decreasing [30]. The study by Golusiński et al.
[30] on the occurrence of this disease in people under
45 years of age indicates that these cases constitute up to
0.24–9.0 % of all cases, and that this problem is relatively
new. These data show that oral and oropharynx cancers
are common among people over 50; however, they also
occur at a younger age (80.8 and 19.2 %, respectively) [31].
Among patients younger than 50 HPV 16 was detected
more often (22.9 %) than in the group aged 50–59
(12.3 %). In patients 70 years and over was only 3 HPV
positive cases (Table 2).
Table 3 Prevalence of HPV and EBV in different histopathological grades and TN classification
HPV+ n = 45 HPV- n = 109 EBV+ n = 42 EBV- n = 112 p value
G1 7 (15.6) 7 (6.4) 4 (9.5) 10 (8.9) >0.05
n = 14
G2 37 (82.2) 89 (81.7) 34 (81.0) 92 (82.2)
n = 126
G3 1 (2.2) 13 (11.9) 4 (9.5) 10 (8.9)
n = 14
P <0.05* >0.05
T1 0 0 0 0 >0.05
n = 0
T2 7 (15.6) 26 (23.8) 6 (14.3) 27 (24.1)
n = 33
T3 9 (20.0) 22 (20.2) 8 (19.0) 24 (21.4)
n = 31
T4 29 (64.4) 60 (55.0) 28 (66.7) 61 (54.5)
n = 89
p >0.05 >0.05
No 6 (13.3) 24 (22.0) 26 (61.9) 4 (3.6) >0.05
n = 30
N1 6 (13.3) 26 (23.9) 7 (16.7) 25 (22.3)
n = 32
N2 25 (55.6) 52 (47.7) 7 (16.7) 70 (62.5)
n = 77
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HPV and EBV. It was found out that the largest number
of smoking patients were in the group infected with
HPV 16 virus (83.3 %; Table 2). Probably, there is a cor-
relation between smoking and HPV 16 infection on the
one hand and oropharyngeal squamous cell carcinoma,
on the other [32]. Merne et al. [33] suggest a possible
synergy between tobacco components and viral onco-
genes, especially HPV16 E6/E7 in transformation of oral
epithelial cells. Studies by Haukioja et al. [34] found out
that smoking is a risk factor for a persistent oral HPV
infection. On the other hand, persistent HPV infection
in the oral mucosa might increase the risk of developing
oral cancer [35].
A number of authors emphasize the role of EBV in the
development of OSCC [14, 15, 20].
Zur Hausen drew attention as early as 1976 to the possi-
bility of the involvement of EBV in human cancer [36].
Jaloluli et al. [18] observed the presence of EBV in 55 % of
samples from 8 different countries. The frequency of oc-
currence of EBV virus varies in different populations.Opinions on the role of EBV in OSCC are different. Lit-
erature provides a wide range of preponderance for oral,
pharynx and larynx viral infections. Nevertheless, the ob-
tained research results suggest that the pathogenesis of
oral squamous cell carcinoma is not directly connected
with Herpesviridae infection in the oral cavity [37]. EBV
DNA was detected in our research in 27.3 % of the cases
(42/154), most often in the 50–59 years old group (31.4 %;
Table 2). The frequency of EBV DNA in oropharyngeal
cancer was slightly higher 29 % (18/62) compared with
the oral cavity – 26.1 % (24/92) (Fig. 1). This low infection
rate may result from the fact that formalin-fixed, paraffin-
embedded tissues was examined.. The presence of the EBV
is most likely connected with more aggressive types of oral
tumors, particularly in groups of immunosuppressed pa-
tients [38]. Infection with EBV can be of importance since
EBV is widespread in the human population (antibodies to
EBV have approximately 95 % of adults). The infection
may be asymptomatic and life-long [39]. According to Kis
et al. [40], the prevalence of Epstein-Barr virus in OSCC
patients is significantly higher than in the healthy group
Polz-Gruszka et al. Infectious Agents and Cancer  (2015) 10:37 Page 6 of 7and higher than that in other mucosa pathologies such as
oral leukoplakia and oral lichen planus (73.8, 19.1, 29.5 and
46.6 %, respectively).
Some authors find a connection between EBV infection
(especially co-infection with papillomaviruses) and squa-
mous cell carcinoma of the tongue and oropharyngeal
sites [14, 17, 41]. In our study HPV-EBV co-infection was
detected only in 7.8 % of samples (Fig. 1). This low per-
centage can not support that co-infection plays a role in
OSCC. However, it cannot be completely exluded. Jalouli
et al. [42] studied tissue samples obtained from patients
with oral cancers and they showed that prevalence of
HPV and EBV infections is common and may influence
the oral cancer development. Co-infection by multiple
oncogenic viruses may be an important risk factor in the
development of OSCC [17, 43]. Jiang et al. [17] suggest
that coinfected cells can have a higher tumorigenic poten-
tial than normal cells, and that co-infection of both HPV
and EBV may have a more profound effect on invasion
than proliferation.
The question remains whether in these cases we have to
do with co-infection or superinfection. It is known that
chronic virus infection affects the immunological answer
of the host. Primary infection with non-oncogenic virus
can favour superinfection with oncogenic virus capable of
cancer transformation. The oncogenic potential of HPV is
related to the expression of E6 and E7, the oncogenic po-
tential of EBV – to the expression of LMP-1 and LMP-2.
Toll-like receptors (TLRs) play a critical role in the early
innate immune response to the invading pathogens by
sensing a microorganism and they are involved in sensing
endogenous danger signals [44, 45]. Fathallah et al [45]
established that the EBV oncoprotein latent membrane
protein 1 (LMP1) is a strong inhibitor of TLR9 transcrip-
tion, which can favour the aforementioned superinfection.
A limitation in our studies is a too small number of cases
of EBV/HPV, coinfection, which makes the epidemio-
logical analysis of this group of patients impossible.
In conclusion, the present study shows that in major
patients from Southeastern region of Poland with oro-
pharyngeal cancer HPV type 16 was detected but in oral
cavity cancer other mixed infections were observed (i.e.
51, 52, 59, 66, 68, 71, 74). HPV 16 was detected more
often among patients younger than 50 age of years,
whereas the mixed HPV in the group aged 50–59. EBV
may play a role in the development of OSCC. Future
both epidemiological and studies on the mechanisms of
co-infection and/or superinfection and their role in oral
squamous cell carcinoma are necessary. The knowledge
about these mechanisms may provide targets for therapy
and for development of diagnostic methods.Competing interests
The authors declare that they have no competing interests.Authors’ contribution
DP-G: Conceived of the study, its design, data analysis, manuscript
preparation; KM: Data and clinical samples collection; AS: Carried out the
molecular identification; MP-D: Data analysis, coordination and helped to
draft the manuscript, review; All authors read and approved the final
manuscript.
Acknowledgements
This study was supported by a Research Grant from the Medical University,
Lublin, Poland (DS 233).
We are thankful to prof. Wiesław Gołąbek (Chair and Department of
Otolaryngology and Laryngological Oncology in Lublin 1998–2010) for his
help in clinical material collection.
Author details
1Department of Virology, Medical University of Lublin, ul. Chodźki 1, 20-093
Lublin, Poland. 2Chair and Department of Otolaryngology and Laryngological
Oncology, ul. Jaczewskiego 8, 20-054 Lublin, Poland.
Received: 4 May 2015 Accepted: 2 September 2015
References
1. Didkowska J, Wojciechowska U, Zatoński Z. Cancer in Poland in 2011. Warsaw:
Oncology Centre- Oncology Institute Maria Skłodowska- Curie; 2013.
2. Alibek K, Kakpenova A, Yeldar Baiken Y. Role of infectious agents in the
carcinogenesis of brain and head and neck cancers. Infect Agent Cancer.
2013;8:7–16.
3. Garbuglia AR. Human papillomavirus in head and neck cancer. Cancers.
2014;6:1705–26.
4. IARC. Monographs on the evaluation of carcinogenic risks to humans. In:
Cancer IARC, ed. Lyon, France: World Health Organization; 2007. p. 670.
5. IARC. Monographs on the evaluation of carcinogenic risks to humans A
review of human carcinogens. Biological agents. Lyon: World Health
Organization; 2012. p. 255.
6. Syrjänen KJ, Syrjänen SM, Lamberg MA, Pyrhönen S. Human papillomavirus
(HPV) involvement in squamous cell lesions of the oral cavity. Proc Finn
Dent Soc. 1983;79:1–8.
7. Jalouli J, Ibrahim SO, Mehrotra R, Jalouli MM, Sapkota D, Larson PA, et al.
Prevalence of viral (HPV, EBV, HSV) infections in oral submucous fibrosis and
oral cancer from India. Acta Otolaryngol. 2010;130:1306–311.
8. Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal
carcinoma: systematic review and meta-analysis. Hum Pathol. 2013;44:983–91.
9. Gillison M, Castellsague X, Chaturvedi A, Goodman M, Smijders P,
Tommasino MA, et al. Comparative epidemiology of HPV infection and
associated cancers of the head and neck and cervix. Int J Cancer.
2014;134:497–507.
10. Peh SC, Kim LH, Mun KS, Tam EL, Sam CK, Poppema S. Epstein-Barr virus
(EBV) subtypes and variants in malignant tissue from Malaysian patients.
J Clin Exp Hematopathol. 2003;43:61–9.
11. Alipov G, Nakayama T, Nakashima M, Wen ChY, Niino D, Kondo H, et al.
Epstein-Barr virus-associated gastric carcinoma in Kazakhstan. World J
Gastroenterol. 2005;11:27–30.
12. Proceedings of the IARC working group on the evaluation of carcinogenic
risks to tumors. Epstein-Barr virus and Kaposi’s sarcoma Herpesvirus/Human
herpesvirus 8. Lyon, France, 17–24 June 1997. IARC Monogr Eval Cacinog
Risks Hum. 1997;70:1-492.
13. Perera RA, Samaranayake LP, Tsang CSP. Shedding dynamics of Epstein-Barr
virus: A type 1 carcinogen. Arch Oral Biol. 2010;55:639–47.
14. Slots J, Saygun I, Sabeti M, Kubar A. Epstein-Barr virus in oral diseases.
J Periodontal Res. 2006;41:235–44.
15. Chen MR. Epstein-Barr virus, the immune system, and associated diseases.
Front Microbiol. 2011;2:5.
16. Grinde B, Olsen I. The role of viruses in oral disease. J Oral Microbiol. 2010;12:2.
17. Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, et al.
Association between human papilloma virus/Epstein-Barr virus co-infection
and oral carcinogenesis.
J Oral Pathol Med. 2015;44:28–36.
18. Jalouli J, Jalouli MM, Sapkota D, Ibrahim SO, Larron PA, Sand L. Human
papillomavirus, herpes simplex virus and Epstein-Barr virus in oral squamous
cell carcinomas from eight different countries. Anticancer Res. 2012;32:571–80.
Polz-Gruszka et al. Infectious Agents and Cancer  (2015) 10:37 Page 7 of 719. Sobin LH, Gospodarowicz M, Wittekind C, editors. TNM classification of
malignant tumours 7th edition. Washington DC: Wiley-Blackwell; 2009. 22–45.
20. Cardesa A, Gale N, Nadal A, Zidor N. Squamous cell carcinoma in World
Heath Organization Classifiation of Tumours. Pathology and Genetics: Head
and Neck Tumours. Barnes L, Eveson JW, Reichart P, Sidnousky (eds.) Lyon,
International Agency for Research on Cancer, 2010; 118-121.
21. Castro Peixoto Patury Galvao T, Busolotti I. Prevalance of Human
papillomavirus (HPV) in oral and oropharynx. Rev Bras Otorrinolaringol.
2006;2:1–14.
22. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP,
et al. Human papillomavirus infection as a prognostic factor in carcinomas
of the oral cavity and oropharynx. Int J Cancer. 2003;104:336–44.
23. Wang D, Ritchie JM, Smith EM, Zhang Z, Turek LP, Haugen TH. Alcohol
dehydrogenase 3 and risk of squamous cell carcinoma of the head and
neck. Cancer Epidemiol Biomarkers Prev. 2005;14:626–33.
24. Sathish N, Wang X, Yuan Y. Human Papillomavirus (HPV)-associated oral
cancers and treatment strategies. J Dent Res. 2014;93:29S–36S.
25. Robinson M, Suh Y, Paleri V, Devlin D, Ayaz B, Pertl L, et al. Oncogenic
human papillomavirus-associated nasopharyngeal carcinoma: an
observational study of correlation with ethnicity, histological subtype and
outcome in a UK population. Infect Agent Cancer. 2013;8:30.
26. Zhao D, Xu Q, Chen X, Fan M. Human Papillomavirus as an Independent
Predictor in Oral Squamous Cell Cancer. Int J Oral Sci. 2009;1:119–25.
27. Mirghani H, Amen F, Moreau F, Guigay J, Ferchion M, Melkane AE, et al.
Human papillomavirus testing in oropharyngeal squamous cell carcinoma:
What the clinician should know. Oral Oncol. 2014;50:1–9.
28. Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status
upon head and neck squamous cell carcinoma. Oral Oncol. 2014;50:565–74.
29. Khode SR, Dwivedi RC, Rhys-Evans P, Kazi R. Exploring the link between
human papilloma virus and oral and oropharyngeal cancers. J Cancer Res
Ther. 2014;10:492–98.
30. Golusiński W, Waśniewska E, Kaczmarek J, Kędzia D, Wróbel M, Malinowska
B. Patients under 45 years of age “young adults” with head and neck
squamous cell carcinoma. Retrospective, multivariable analysis–preliminary
report. Otolaryngol Pol. 2003;57:185–9.
31. Wojciechowska U, Didkowska J, Zatoński W. Cancer in Poland in 2003. Warsaw,
Poland: Oncology Centre- Oncology Institute Maria Skłodowska- Curie; 2005.
32. Chakrobarty B, Roy JG, Majumdar S, Uppala D. Relationship among tobacco
habits, human papilloma virus (HPV) infection, p53 polymorphism/mutation
and the risk of oral squamous cell carcinoma. J Oral Maxillofac Pathol.
2014;18:211–6.
33. Merne M, Rautava J, Ruutu M, Syrjanen S. Smokeless tobacco increases
aneuploidy in oral HPV16E6/E7-transformed keratinocytes in vitro. J Oral
Pathol Med. 2014;43:685–90.
34. Haukioja A, Asunta M, Söderling E, Syrjänen S. Persistent oral human
papillomavirus infection is associated with smoking and elevated salivary
immunoglobulin G concentration. J Clin Virol. 2014;61:101–6.
35. Rautava J, Syrjänen S. Human papillomavirus infections in the oral mucosa.
J Am Dent Assoc. 2011;142:905–14.
36. Hausen Z. Biochemical approaches to detection of Epstein-Barr virus in
human cancer. Cancer Res. 1976;26:678–80.
37. Saravani S, Miri-Moghaddam E, Sanadgol N, Kadeh H, Nazeri MR. Human
herpesvirus-6 and Epstein-Barr virus infections at different histopathological
grades of oral squamous cell carcinomas. Int J Prev Med. 2014;5:1231–8.
38. Slots J. Herpesviruses in periodontal diseases. Periodontol 2000. 2005;38:33–62.
39. Shah KM, Young LS. Epstein-Barr virus and carcinogenesis: beyond Burkitt’s
lymphoma. Clin Microbiol Infect. 2009;15:982–88.
40. Kis A, Feher E, Gall T, Tar I, Boda R, Toth ED, et al. Epstein-Barr virus
prevalence in oral squamous cell cancer and potentially malignant oral
disorders in an eastern Hungarian population. Eur J Oral Sci. 2009;117:537–40.
41. Goldenberg D, Benoit NE, Begun S, et al. Epstein-Barr virus in head and
neck cancer assessed by quantitative polymerase chain reaction.
Laryngoscope. 2004;114:1027–31.
42. Jalouli J, Ibrahim SO, Sapkota D, Jalouli MM, Vasstrand EN, Horsch JM, et al.
Presence of human papilloma virus, herpes simplex virus and Epstein-Barr
virus DNA in oral biopsies from Sudanese patients with regard to toombak
use. J Oral Pathol Med. 2011;19:599–604.
43. Al Moustafa AE, Chen D, Ghabreau L, Akil N. Association between human
papillomavirus and Epstein-Barr virus infections in human oral
carcinogenesis. Med Hypotheses. 2009;73:184–6.44. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9
expression and function is abolished by the cervical cancer-associated
human papillomavirus type 16.
J Immunol. 2007;178:3186–97.
45. Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, et al. EBV
latent membrane protein 1 is a negative regulator of TLR9. J Immunol.
2010;185:6439–47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
